 |
|
|
| |
GS-6620, A Novel Anti-Hepatitis C Virus Nucleotide Prodrug, Has A High In Vitro Barrier To Resistance
|
| |
| |
Reported by Jules Levin
EASL 2011 Berlin March 31-Apr 2
M Fenaux, G Cheng, E Mabery, K Ku, S Eng, J Vela, J Feng, W Delaney, H Mo, A Ray and W Zhong
Gilead Sciences, Inc., Foster City, CA, U.S.A.
References
1. Cheng G, Fenaux M, Mabery E, et al. Nucleotide Inhibitor Resistance Selections Using GT2a Infectious Virus: PSI-7851 and GS-6620 Select for a Novel Resistance Pathway Including Substitutions of M289V/L Followed by S282T. Poster No.1198, EASL
2011
2. Ray A, Feng J, Wang T, et al. GS-6620: A Liver Targeted Nucleotide Prodrug with Potent Pan-Genotype Anti-Hepatitis C Virus Activity In Vitro. Poster No. 1233, EASL 2011
3. Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008;61:1205-16.
4. Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, et al. Replication fi tness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005;49 (5):2059-69.
5. McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008;52 (5):1604-12.
|
| |
|
|
|
|
|
